



OXSTEM FURTHER STRENGTHENS MANAGEMENT TEAM THROUGH APPOINTMENT OF CHIEF SCIENTIFIC OFFICER

Oxford, UK, 10th September, 2018.

OxStem Limited is pleased to announce the appointment of Dr. Georg C. Terstappen to the role of Chief Scientific Officer (CSO).

Georg Terstappen has 25 years' experience in pharmaceutical R&D obtained in leading positions in international companies including Bayer, GlaxoWellcome, GlaxoSmithKline (GSK), Abbott / AbbVie, and in the biotech industry where he was Co-founder and CSO of a 'start-up' drug discovery company, Siena Biotech S.p.A. Prior to joining OxStem, Georg was Head of Discovery Biology at AbbVie in Ludwigshafen (Germany), and most recently Head of Platform Technologies & Science China at GSK's R&D Centre in Shanghai, with responsibility for preclinical drug development.

In the European R&D framework Georg has held leading positions: He was Vice-Chair of the Innovative Medicines Strategy Group (InnoMedS) in the context of EFPIA and IMI (Innovative Medicines Initiative) and is a founding member and Co-Chair of the Strategic Governing Group for Neurodegeneration. In addition, he was also for more than ten years Adjunct Professor at several European universities and leader of European-wide research programs funded by the EU and public-private partnerships funded by IMI.

Georg has a First-class Honours degree in biology and prior to joining the pharmaceutical industry in 1992, has conducted research at the Max-Planck-Institute in Cologne (Germany) and the Federal Research Centre Juelich (Germany) for which he received a Ph.D. in Natural Sciences.

His major accomplishments in terms of innovative research and its practical application are demonstrated by 80 scientific publications, 15 patents and identification/development of many new drug targets, bioassay systems, biomarkers, drug delivery technologies and preclinical/clinical drug candidates.

Reporting to the CEO and working in close collaboration with OxStem Scientific Founders and Principal Investigators at the University of Oxford, the CSO will assume executive responsibility for delivery on OxStem's discovery & development plans across its portfolio of six programmes.

Dr. Michael Stein, Chairman and CEO, OxStem commented: "On behalf of the entire Company, I warmly welcome Georg to OxStem and we are thrilled to have attracted such an accomplished Drug Hunter to the OxStem Team. Georg brings extensive R&D management experience to OxStem and his track record of delivery in both pharma and biotech is well-evidenced. He joins OxStem at a time of significant growth and acceleration in our discovery programmes and we look forward to working with Georg on our important mission to deliver innovative medicines based on the translation of our breakthrough science."

Angela Russell, Professor of Medicinal Chemistry, University of Oxford, Scientific Co-founder and Director of Chemistry of OxStem further commented: "Georg's experience in discovery biology and translational research, is highly complementary to the strong medicinal chemistry and deep disease area expertise of the OxStem scientific team. We look forward to a close collaboration with Georg to realise OxStem's programme objectives."

Media enquiries to Amy Varney / Raymond Spencer: info@oxstem.com